explore -WSS

explore

author：comprehensive 2025-09-29 22:46:15 - browse：72512

LONDON — In a bid to expand its pipeline of inflammation-targeting drugs, Sanofi said Tuesday it was acquiring California-based Inhibrx in a deal worth up to $2.2 billion.

The core of the deal is Inhibrx’s experimental therapy for AATD, a disease that progressively damages the lungs and liver. The medicine, INBRX-101, is designed to reduce inflammation and stave off further damage to the tissue. Inhibrx has completed Phase 1 testing of the drug and is enrolling patients in a Phase 2 trial.

Inhibrx’s other drug candidates, including its line of cancer-targeting immunotherapies, will be portioned out into a new company that will continue to be called Inhibrx. Mark Lappe, the founder and CEO of Inhibrx, will lead the spun-out company.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Readout LOUD podcast: ALS dilemma, first MASH drug, and more

WSS

Marc Tessier

RaDonda Vaught links Vanderbilt hospital issues to patient death

Biden announces an advanced cancer research initiative

Biden jokes that Republicans may impeach him because inflation is starting to cool down

WuXi out of biotech trade group, U.S. and China relations to blame

HHS secretary Becerra pressed on Change HealthCare cyberattack

focus

explore

hotspot

Hollywood unions extend contract negotiations for actors

Readout Newsletter: Bristol, Sangamo, Gilead, and more

How to save PrEP access — and even expand it

As the dark side of IVF slowly comes into focus, even more transparency is needed

At least 13 dead in Texas as scorching temps continue

FDA advisers back CAR

Dobbs anniversary: the lost opportunity of abortion as health care

Stoke drug shows lower activity against childhood epilepsy

What does generative AI mean for health care? We asked experts

Boston's new lab space is opening empty

knowledge

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

McConnell had minor fall 2 weeks ago, uses wheelchair periodically to get around: Sources

VC firm RA Capital starts a new synthetic biology incubator

John Green on his newest strategy for fighting tuberculosis

Bryan Kohberger seeks indictment dismissal in Idaho college killings case

McConnell had minor fall 2 weeks ago, uses wheelchair periodically to get around: Sources

Wikipedia

Wikipedia

knowledge

entertainment